Emcure Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9piscrr2fdus2j1ai629kc8d.pdf

Key Takeaways


The Novo Nordisk Partnership & What It Unlocks

Satish Mehta: "we became the only company to launch the innovator drug in the game-changing semaglutide category."

International Business: The Growth Engine

Samit Mehta: "Again, I can't put a number to the market potential, though we think it's a revolutionary introduction in the field of HIV, both therapeutically and prophylactically, it offers the opportunity for cure. So market could be huge."

Domestic Business & Therapy Mix


Margin Structure & the Path to 23-24%

Vikas Thapar: "over a 3- to 5-year horizon, we would anticipate at least a 300 to 400 basis point improvement in our EBITDA margin profile with roughly 100 basis points or so improvement year-on-year for the next 2 to 3 years is what we have guided to in the past as well."

Balance Sheet & Capital Allocation


Policy Tailwind: Bio-Pharma SHAKTI


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthLow to mid-teens compounded growth rate3-5 year horizon
FY27 revenue guidanceSimilar to ~13% growth guided for FY26, which the company is tracking slightly ahead ofFY27
EBITDA margin improvementAt least 300-400 bps total improvement, roughly 100 bps per year, targeting 23-24%3-5 years
International market growth (Europe & Canada)Compounded low-teens growth rate3-5 years
Net debt reductionNet debt to go off the balance sheet24-36 months
Cash flow positiveCompany should be cash flow positive, barring acquisitionsBy end FY28
Annual capex₹350-400 crores gross block addition per yearNext 2-3 years
Amphotericin B Europe launchesLaunches across EuropeBy end of year
Amphotericin B revenue contributionMaterial growth expectedFrom next year onwards
Canada growthMid-teens growthCurrent year
Gross marginIn the ~60% ballparkFY26

Key Metrics

MetricQ3 FY26
Revenue from operations₹2,363 cr, +20.4% YoY
Domestic revenue₹1,025 cr, +15.4% YoY
International revenue₹1,338 cr, +24.5% YoY
Europe revenue₹464 cr, +29.6% YoY
Canada revenue₹397 cr, +12.8% YoY
Emerging markets revenue₹477 cr, +30.7% YoY
Gross margin59.3%, vs 60.1% in Q3 FY25; decline due to Sanofi OAD in-licensing and business mix
EBITDA₹460 cr, +27.2% YoY, excluding other income
EBITDA margin19.5%, vs 18.4% in Q3 FY25 and 19.3% in Q2 FY26
Profit after tax₹231 cr, +48% YoY; includes exceptional expense of ₹38 cr for Labour Code
Adjusted PAT₹260 cr, +65% YoY, excluding Labour Code impact
Net debt₹1,203 cr; increase primarily due to Zuventus minority stake payout
Domestic base business growth10%+, ex of Sanofi OAD in-licensing portfolio
In-licensing contribution to total revenue6% to 7% of total revenue; low to mid-teens of domestic business
MR productivity~7, vs 6 to 6.1 in same quarter last year